Company Overview
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Recent Developments
- Dec 2025 Revenue of $30.91M (+209.1% YoY); net profit $-209.47M.
- Trailing 12 Months Year-on-year growth — revenue +209.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.11% |
| 1 Year: | 209.14% |
Stock Price Performance
| 1 Year: | -1.56% |
| 6 Months: | +23.75% |
| 3 Months: | +112.80% |
| 1 Month: | +33.59% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)68.48 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 26.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VSTM Verastem, Inc. R2KR3KPHARMA | 7.90 | -2.74 | $715.45M | 0.00% | -97.68% | - | 2.11% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | 10.00M | 15.51M | 1.21M | 1.67M | 3.14M | 9.03M | 3.62M | 5.06M | 4.31M | 78.65M | 506.00K | 1.01M | 500.00K | 2.00K | 2.60M | - | - | - | - | - | - | 10.00M | - | 0 | 2.14M | 11.24M | 17.54M | 18.67M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 446.00K | 1.96M | 2.89M | 3.05M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.69M | 9.28M | 14.64M | 15.62M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 44.17M | 45.45M | 50.00M | 56.12M | 60.52M | - |
| Operating Income | -15.53M | -11.96M | -8.43M | -8.71M | -8.06M | -11.80M | -13.15M | -13.47M | -23.14M | -18.05M | -20.76M | -18.19M | -21.57M | -34.26M | -34.67M | -38.28M | -26.10M | -33.29M | -26.36M | -21.26M | 15.02M | -16.75M | -14.11M | -15.94M | -14.85M | -16.98M | -21.40M | -17.71M | -19.34M | -20.29M | -21.31M | -28.06M | -18.28M | -37.03M | -44.17M | -43.76M | -40.72M | -41.48M | -44.90M | -32.71M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -51.90M | -25.59M | -97.91M | -32.20M | -35.93M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 192.00K | 212.00K | 319.00K | 415.00K | 382.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -52.10M | -25.93M | -98.52M | -32.92M | -36.59M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -15.45M | -11.86M | -8.29M | -8.57M | -7.92M | -11.65M | -13.01M | -13.44M | -23.13M | -18.23M | -21.05M | -18.37M | -21.67M | -11.35M | -38.10M | -42.19M | -30.14M | -38.77M | -37.99M | -23.01M | 13.14M | -19.86M | -15.03M | -16.90M | -22.79M | -16.96M | -21.95M | -18.09M | -15.71M | -24.28M | -20.00M | -33.86M | -8.26M | -23.97M | -52.10M | -25.93M | -98.52M | -32.92M | -36.59M | -34.67M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.41 | -0.30 | -0.29 | -0.37 | -0.52 | -0.57 | -0.41 | -0.51 | -0.35 | -0.14 | 0.08 | -0.12 | -0.09 | -0.10 | -0.13 | -0.09 | -0.12 | -0.09 | -0.08 | -1.37 | -0.75 | -1.26 | -0.31 | -0.60 | -0.96 | -0.62 | -1.35 | - | -0.46 | -0.35 |
| R&D Expense | 11.30M | 7.69M | 4.18M | 4.49M | 4.22M | 6.89M | 8.38M | 9.04M | 17.74M | 11.25M | 10.93M | 12.38M | 11.57M | 8.76M | 9.76M | 11.35M | 12.22M | 12.46M | 10.92M | 9.34M | 10.96M | 10.15M | 8.90M | 9.73M | 9.32M | 13.64M | 14.89M | 11.29M | 12.02M | 12.89M | 13.95M | 17.71M | 18.06M | 24.75M | 29.15M | 24.79M | 28.99M | - | 38.22M | 41.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 26.72M | 17.46M | 88.52M | 2.05M | 2.60M | 0 | 10.00M | 30.91M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 5.30M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 2.60M | 0 | 10.00M | 25.62M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 75.53M | 92.08M | 124.96M | 195.75M |
| Operating Income | -13.70M | -32.23M | -41.40M | -53.61M | -58.20M | -37.00M | -67.80M | -94.78M | -132.34M | -49.36M | -61.41M | -72.94M | -92.08M | -114.96M | -170.13M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | -71.56M | -83.17M | -125.86M | -207.60M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | 2.14M | 4.14M | 4.56M | 1.14M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | -73.81M | -87.37M | -130.45M | -209.47M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 185.00K | 0 |
| Net Income | -13.68M | -31.98M | -41.20M | -53.37M | -57.87M | -36.44M | -67.80M | -72.43M | -149.21M | -67.73M | -71.20M | -73.81M | -87.37M | -130.64M | -209.47M |
| Diluted EPS | - | - | - | - | - | -0.99 | -1.76 | -1.37 | -2.00 | -0.44 | -4.90 | -4.57 | -3.96 | -3.66 | -3.02 |
| R&D Expense | 9.88M | 21.71M | 25.93M | 35.45M | 40.56M | 19.78M | 46.42M | 43.65M | 45.78M | 41.38M | 39.35M | 50.56M | 61.36M | 81.33M | 114.60M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 59.04M | 92.92M | 125.26M | 98.65M | 113.09M | 83.63M | 89.79M | 277.24M | 145.05M | 154.35M | - | 95.05M | 149.72M | 101.54M | 246.44M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 92.87M | 143.68M | 94.96M | 223.41M |
| Cash & Equivalents | 3.58M | 33.90M | 10.10M | 18.89M | 33.90M | 24.87M | 32.35M | 82.18M | 129.87M | 43.51M | 67.78M | - | 74.93M | 77.91M | 88.82M | 204.99M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.83M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 516.00K | 31.00K | 0 | 200.00K | - |
| Total Liabilities | - | - | - | - | - | - | 11.33M | 32.11M | 152.94M | 137.87M | 39.08M | - | 47.66M | 92.34M | 130.43M | 189.25M |
| Current Liabilities | - | 3.15M | 2.40M | 7.80M | 9.20M | 10.11M | 10.99M | 17.13M | 37.08M | 29.89M | 17.09M | - | 21.66M | 26.38M | 30.97M | 72.27M |
| Long Term Debt | - | - | - | - | - | - | - | 14.83M | - | - | - | - | 24.53M | 40.09M | 40.72M | 81.33M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 27.07M | 41.56M | 42.25M | 87.17M |
| Total Equity | -687.00K | -12.77M | 90.47M | 117.45M | 88.77M | 102.47M | 72.30M | 57.68M | 124.30M | 7.17M | 115.27M | - | 47.39M | 57.37M | -28.89M | 57.20M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 16.71M | 25.28M | 44.78M | 77.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -45.56M | -29.48M | -57.31M | -74.52M | -138.52M | -33.51M | - | -63.67M | -86.46M | -104.77M | -137.51M |
| Investing Cash Flow | - | - | - | - | -27.06M | 36.93M | 43.95M | -138.38M | 89.61M | -47.36M | - | 66.19M | -44.45M | 59.97M | -9.62M |
| Financing Cash Flow | - | - | - | - | 63.59M | -5.00K | 63.18M | 261.16M | -2.44M | 69.63M | - | 51.78M | 134.19M | 54.78M | 263.31M |
| Capital Expenditure | -785.00K | -310.00K | -56.00K | -2.43M | -211.00K | -39.00K | - | -1.51M | -7.00K | -33.00K | -196.00K | - | - | -28.00K | -9.62M |
| Free Cash Flow | - | - | - | - | -45.77M | -29.52M | - | -76.02M | -138.53M | -33.54M | - | -63.67M | -86.46M | -104.80M | -147.13M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | 54.30M | 3.29M | 9.98M | 116.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 100.0% | - | 100.0% | 82.9% |
| Operating Margin % | - | - | - | - | - | - | - | -354.8% | -758.1% | -55.8% | -2,991.2% | -2,809.6% | - | -1,149.6% | -550.3% |
| Net Margin % | - | - | - | - | - | - | - | -271.1% | -854.8% | -76.5% | -3,468.1% | -2,843.3% | - | -1,306.4% | -677.6% |
| ROE % | 107.2% | -35.4% | -35.1% | -60.1% | -56.5% | -50.4% | -117.5% | -58.3% | -2,079.9% | -58.8% | - | -155.8% | -152.3% | 452.1% | -366.2% |
| ROCE % | -24.5% | -35.6% | -35.2% | -59.9% | -56.5% | -50.9% | -93.3% | -39.5% | -114.9% | -36.0% | - | -99.4% | -74.7% | -162.9% | -97.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.15% | 9.19M | $66.37M |
| 2 | Armistice Capital, LLC | 7.76% | 7.02M | $50.71M |
| 3 | RTW Investments LP | 7.33% | 6.64M | $47.91M |
| 4 | Deep Track Capital, Lp | 6.34% | 5.74M | $41.45M |
| 5 | State Street Corporation | 5.67% | 5.13M | $37.07M |
| 6 | Rosalind Advisors, Inc. | 4.40% | 3.99M | $28.78M |
| 7 | Vanguard Capital Management LLC | 4.25% | 3.85M | $27.81M |
| 8 | Nantahala Capital Management, LLC | 3.96% | 3.58M | $25.88M |
| 9 | Stonepine Capital Management, LLC | 3.70% | 3.35M | $24.18M |
| 10 | Vanguard Portfolio Management LLC | 3.61% | 3.27M | $23.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VSTM
Verastem Oncology to Participate in Upcoming September Investor Conferences
BOSTON, September 02, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to parti…
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views
The average assessed fair value for Verastem has been cut from $16.13 to $14.75, pointing to a moderate reset in price targets. Analysts link this change to a more cautious stance on competition and revenue assumptions, even as many still f…
Verastem (VSTM) Q2 2026 Earnings Call Transcript
Revenue surged on CO-PACK launch as cash runway extends into late 2027.
Verastem Q2 Earnings Call Highlights
Verastem (NASDAQ:VSTM) reported second-quarter 2026 net product revenue of $25.1 million from sales of its AVMAPKI FAKZYNJA CO-PACK, as the company said increased new patient starts, refills and physician adoption supported a rebound in com…
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong Revenue Rebound and Strategic ...
Verastem Inc (VSTM) reports $25.1 million in Q2 net product revenues, secures non-dilutive financing, and progresses its KRAS G12D inhibitor program with promising clinical data.
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026
BOSTON, July 23, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and we…
VSTM — Frequently Asked Questions
What is the current share price of Verastem, Inc. (VSTM)?
As of 2026-09-07 16:24 PDT, Verastem, Inc. (VSTM) trades at $7.90 on NasdaqCM. Its 52-week range is $3.45 to $10.77.
What is the market capitalisation of VSTM?
Verastem, Inc. (VSTM) has a market capitalisation of $715.45M on NasdaqCM.
What is the P/E ratio of VSTM?
VSTM trades at a trailing price-to-earnings (P/E) ratio of -2.74. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 7.24.
Is VSTM a good stock to buy?
This page provides a data-driven analysis of Verastem, Inc. (VSTM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.